Journey Medical Corporation revealed that DFD-29—minocycline modified release capsules—may be more effective at treating patients with papulopustular rosacea than current treatments, according to a report from Healio. In the randomized, double-blind MVOR-01 and MVOR-02 phase II trials, researchers administered 40 mg of DFD-29 to 240 patients, 40 mg of doxycycline to 240 patients, and a placebo to 160 patients—and discovered that DFD-29 may have been far more effective than doxycycline, placebo, and lower doses of DFD-29. “There have been no serious adverse reactions in the two studies thus far. The feedback from investigators has been that their patients are generally happy with the study treatment,” highlighted Srinivas Sidgiddi, MD, Vice President of Clinical Development and Medical Affairs at Journey Medical Corporation. The researchers recently completed enrollment for a phase III trial evaluating the safety and efficacy of the medication and expect to apply for a new drug application with the FDA in late 2023.
April 30, 2023